Genesys Capital Research
Investment Thesis
Genesys Capital is a Toronto-based life sciences venture firm that invests in and builds companies in biotechnology, pharmaceuticals and medical technology. The firm describes its approach as "create and build": it works closely with scientific founders, often starting from university and hospital research, and acts as a thought partner on board structure, capital strategy and business development. Portfolio CEOs describe a hands-on, "sweat equity" style. The firm's tagline is "Where Big Ideas & Smart Risks Drive Medical Breakthroughs."
Stage Focus
Genesys is an early-stage specialist. Its exit history shows a pattern of founding or Series A lead positions (Fusion Pharmaceuticals as founding Series A investor, Inversago and Epocal as Series A leads, Fairhaven as Seed lead). Its newest vehicle, the Genesys University Seed Fund, targets pre-seed and seed companies spun out of universities and hospitals. Later-stage participation is limited to follow-ons and occasional PIPE or Series C positions.
Check Size
The firm does not publish check sizes for its main funds. Third-party data (Venture Capital Archive) lists the University Seed Fund at roughly $70K to $710K per company. Main-fund checks are not verified and are left blank in the structured record.
Lead Tendency
The exit table repeatedly shows "Lead Investor" on Series A and Seed rounds, with a director seat, and in several cases the chair role (Fusion, Inversago). The firm leads early rounds and takes board seats. Later rounds in portfolio companies (for example Enspire DBS Therapy's $10.3M Series B1 in January 2026) are syndicated.
Recent Activity
- October 13, 2026: announced the second close of the Genesys University Seed Fund, adding Sunnybrook and UHN as hospital partners.
- July 2026: launched the University Seed Fund with the University of Toronto, McMaster and Venture Ontario; third-party data cites a first close above $30M against a larger target.
- July 9, 2026: Flosonics Medical secured a strategic investment from Denka.
- June 11, 2025: announced the upcoming closing of Genesys Ventures IV LP, described as its largest fund to date, for Canadian medtech and biotech.
- January 13, 2026: Enspire DBS Therapy announced a $10.3M Series B1.
The firm is actively deploying from Fund IV and the University Seed Fund.
Portfolio Highlights
The firm reports 13 exits. The two headline outcomes:
- Fusion Pharmaceuticals: acquired by AstraZeneca in June 2024 for USD $2.4B. Genesys was the founding Series A investor and chaired the board.
- Inversago Pharma: acquired by Novo Nordisk in September 2023 for USD $1.1B. Genesys led the Series A.
Other exits include Naurex (Allergan, 2015, $1.7B), Epocal (Alere, 2013, $225M), Affinium (Debiopharm, 2014, $127M), IDbyDNA (Illumina, 2022, $90M), Xltek (Natus, 2007, $44M) and Ionalytics (Thermo Electron, 2005, $35M). Public-market positions include Invitae and Aptinyx.
Current investments include Adapsyn, Antegrade Medical, BIOS Genomics, CryoStasis, EBT Medical, Enspire DBS Therapy, Feldan Therapeutics, Flosonics Medical, Functional Neuromodulation, Giiant Pharma, Profound Medical, Questat and Veralox Therapeutics. The site shows a "coming soon" placeholder for one further company.
Team
- Damian Lamb, Co-founder and Managing Director: co-founded Genesys in 2000; formerly at MDS Capital; chaired Fusion, Profound and Delex; MSc in molecular neurobiology (McMaster), MBA (Queen's).
- Kelly Holman, Co-founder and Managing Director: co-founded Genesys in 2000; formerly at MDS Capital; part of the lab team that discovered Alzheimer's-related genes; board seats at Adapsyn, Functional Neuromodulation and Questat.
- Jamie Stiff, Managing Director: joined in 2002, partner since 2007; boards include Enspire, Feldan, Giiant and Veralox; MBA (Rotman).
- Jennifer Williams, Partner and Chief Financial Officer.
- Sarah Farr, Principal.
- Stephanie Legere and Laurie Mak, Associates.
- Lisa Low, Senior Vice President, Finance.
Decision Process
A partnership of three managing directors with over 25 years of continuous collaboration. Investment decisions are made by the partnership; there is no solo GP. The firm takes board seats and works closely with management.
Founder Preferences
Scientific founders and entrepreneurs, often from Canadian research institutions, who want an active board partner. The firm values repeat relationships: Epocal's founder returned to Genesys as his first call when starting Questat. CEOs highlight governance, financing strategy and network (including JP Morgan healthcare week).
Geographic Focus
Canada first (the Toronto-Waterloo-Montreal research corridor, with University of Toronto, McMaster, Sunnybrook and UHN partnerships), with investment in the United States. Offices at 123 Front Street West, Toronto.
Gaps
Fund sizes for Funds I to IV, main-fund check sizes and AUM are not published on the site. Stage at investment per portfolio company is not recorded because no per-company round source was read.